Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bogart

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
How to report toxicity associated with targeted therapies?B Cabarrou, J M Boher, E Bogart, et al.
Disability and Rehabilitation|June 25, 2026
Healthcare should be accessible for all: development of the ObServation Tool and Resource for Inclusive Communication in Healthcare (OSTRICH)E Bogart, M Brunner, R Rietdijk, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 28, 2016
Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patientsA Kakkos, L Bresson, D Hudry, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2019
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)A Adenis, J Bennouna, P L Etienne, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
How to report toxicity associated with targeted therapies?B Cabarrou, J M Boher, E Bogart, et al.
Disability and Rehabilitation|June 25, 2026
Healthcare should be accessible for all: development of the ObServation Tool and Resource for Inclusive Communication in Healthcare (OSTRICH)E Bogart, M Brunner, R Rietdijk, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 28, 2016
Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patientsA Kakkos, L Bresson, D Hudry, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2019
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)A Adenis, J Bennouna, P L Etienne, et al.
Pageof 2